These results agree with those of previous studies demonstrating the importance of allelic burden in RUNX1 and its relevance to FPD/AML progression [38], suggesting that RUNX1 alterations could impair the PKCα/β signaling pathway, promoting the disease’s appearance. Here, PRKCA is linked to acute myeloid leukemia.